- Home >
- Clinicals Trials >
- MO44869_GLOASIS
Retour à la liste des essais cliniquesHématologie / cancers du sang
MO44869_GLOASIS
https://clinicaltrials.gov/study/NCT06558604?term=gloasis&rank=1
- Ouvert à Saint-Cloud depuis le : 18/02/2025
- Public cible : Adult
- Phase : Phase II
Description de l'essai
The primary efficacy endpoint is PFS (progression-free survival) at 12 months (end of C17) from the first dose of the study treatment, as determined by central imaging review (Lugano 2014 criteria). Each cohort will be assessed independently.
Url of the trialInvestigateur principal
